NCT05497362

Brief Summary

The proposed study aimed to determine if tDCS can help post-stroke patients with dysarthria.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2016

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2017

Completed
5.1 years until next milestone

First Submitted

Initial submission to the registry

July 23, 2022

Completed
19 days until next milestone

First Posted

Study publicly available on registry

August 11, 2022

Completed
Last Updated

September 2, 2022

Status Verified

September 1, 2022

Enrollment Period

1.2 years

First QC Date

July 23, 2022

Last Update Submit

September 1, 2022

Conditions

Outcome Measures

Primary Outcomes (6)

  • Perceptual speech assessments

    All participants were required to produce a sustained vowel /a/, repeated some syllables (i.e., /pa/, /ta/, /ka/ and /pataka/), produce some single words, read a standard paragraph in Cantonese and had a two-minute conversation with the investigator. A professional grade microphone (SM58, Shure, USA) was used to record the speech production. Experienced speech-language pathologists blinded to the neurological condition and history of each participant analyzed the speech samples independently using a perceptual rating scale including 21 speech dimensions covering eight categories, including pitch, loudness, voice quality, resonance, rate, articulation, tone, and general impression. The speech samples were rated using a seven-point equal-appearing interval scale, with a "1" indicating within typical limit performance and a "7" severely deviated from the normal.

    Change before and after tDCS stimulation at immediately post-treatment

  • Acoustic measurement: Fundamental frequency (F0)

    Fundamental frequency (F0) was obtained from sustained vowel phonation.

    Change before and after tDCS stimulation at immediately post-treatment

  • Acoustic measurement: Frequency perturbation (jitter %)

    Frequency perturbation (jitter %) was obtained from sustained vowel phonation.

    Change before and after tDCS stimulation at immediately post-treatment

  • Acoustic measurement: Intensity perturbation (shimmer %)

    Intensity perturbation (shimmer %) was obtained from sustained vowel phonation.

    Change before and after tDCS stimulation at immediately post-treatment

  • Acoustic measurement: Noise to harmonic ratio (NHR)

    Noise to harmonic ratio (NHR) was obtained from sustained vowel phonation.

    Change before and after tDCS stimulation at immediately post-treatment

  • Acoustic measurement: Harmonic to noise ratio (HNR)

    Harmonic to noise ratio (HNR) was obtained from sustained vowel phonation.

    Change before and after tDCS stimulation at immediately post-treatment

Secondary Outcomes (5)

  • Kinematic measurement: Duration

    Change before and after tDCS stimulation at immediately post-treatment

  • Kinematic measurement: Distance

    Change before and after tDCS stimulation at immediately post-treatment

  • Kinematic measurement: Maximum velocity

    Change before and after tDCS stimulation at immediately post-treatment

  • Kinematic measurement: Maximum acceleration

    Change before and after tDCS stimulation at immediately post-treatment

  • Kinematic measurement: Maximum deceleration

    Change before and after tDCS stimulation at immediately post-treatment

Study Arms (2)

Real tDCS

EXPERIMENTAL

Group 1 (n = 5) received anodal tDCS stimulation and intensive speech and voice therapy; tDCS and speech therapy was applied in 10 daily sessions during a 2-week period, administered on Monday to Friday. The anodal stimulation was delivered to the primary motor cortex (SM1) of the orofacial area.

Device: Real tDCS

Sham tDCS

SHAM COMPARATOR

Group 2 (n = 4) received sham tDCS stimulation and intensive speech and voice therapy. For the sham tDCS group, the same setting of tDCS electrodes was applied on the scalp, but the stimulation only lasted for 30 sec in order to cause a similar sensation on the scalp. tDCS and speech therapy was applied in 10 daily sessions during a 2-week period, administered on Monday to Friday.

Device: Sham tDCS

Interventions

Real tDCSDEVICE

2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 15 minutes. Speech therapy was delivered simultaneously.

Real tDCS
Sham tDCSDEVICE

2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 30 sec. Speech therapy was delivered simultaneously.

Sham tDCS

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Cantonese-speaking adults
  • At least 6 months after their initial stroke
  • Dysarthria post-stroke

You may not qualify if:

  • A personal or family history of epilepsy or seizures
  • A history of another neurological condition
  • Speech disorders
  • Voice disorders
  • Oro-maxillo-facial surgery involving the tongue and/or lip
  • Severe cognitive impairment
  • Severe aphasia
  • Heart disease
  • Metallic foreign body implant
  • On medications that lower neural thresholds (e.g. tricyclines, antidepressants, neuroleptic agents, etc.)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Hong Kong

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

DysarthriaStroke

Condition Hierarchy (Ancestors)

Articulation DisordersSpeech DisordersLanguage DisordersCommunication DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Manwa L Ng, PhD

    The University of Hong Kong

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Double-blinded
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 23, 2022

First Posted

August 11, 2022

Study Start

April 1, 2016

Primary Completion

June 30, 2017

Study Completion

June 30, 2017

Last Updated

September 2, 2022

Record last verified: 2022-09

Data Sharing

IPD Sharing
Will not share

Locations